Mylan, Pfizer Barely Put Dent In EpiPen Antitrust MDL
Law360 (August 20, 2018, 9:53 PM EDT) -- Mylan NV and Pfizer Inc. on Monday largely failed to scale down multidistrict litigation over sky-high prices for emergency allergy treatment EpiPen, as a Kansas federal judge mostly refused to throw out wide-ranging consumer claims of anti-competitive shenanigans.
The setback came in a 128-page ruling from U.S. District Judge Daniel D. Crabtree, who kept alive most of a proposed class action that alleges “one of the most egregious examples of corporate greed and malfeasance in our nation’s history.”
In his ruling, Judge Crabtree preserved allegations brought under the Sherman Act, the Clayton Act, and the Racketeer Influenced and Corrupt Organizations Act. Although Judge Crabtree dismissed a number of...
Stay ahead of the curve
In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.
Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
Create custom alerts for specific article and case topics and so much more!